RT Journal Article
SR Electronic
T1 Clinical efficacy and increased donor strain engraftment after antibiotic pretreatment in a randomized trial of ulcerative colitis patients receiving fecal microbiota transplant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.07.21261556
DO 10.1101/2021.08.07.21261556
A1 Byron J. Smith
A1 Yvette Piceno
A1 Martin Zydek
A1 Bing Zhang
A1 Lara Aboud Syriani
A1 Jonathan P. Terdiman
A1 Zain Kassam
A1 Averil Ma
A1 Susan V. Lynch
A1 Katherine S. Pollard
A1 Najwa El-Nachef
YR 2021
UL http://medrxiv.org/content/early/2021/08/10/2021.08.07.21261556.abstract
AB Fecal microbiota transplant is a promising therapy for ulcerative colitis. Parameters maximizing effectiveness and tolerability are not yet clear, and it is not known to what degree the transmission of donor microbes to patients is important. Here (clinicaltrails.gov: NCT03006809) we have tested the effects of antibiotic pretreatment (neomycin, vancomycin, and metronidazole, 500 mg twice a day for 5 days) and compared two modes of maintenance dose delivery, capsules versus enema, in a randomized, pilot, open-label, 2×2 factorial design with 22 patients analyzed (30 patients randomized) with mild to moderate UC (total Mayo score 4-9). Clinically, the treatment was well-tolerated with favorable safety profile. Patients receiving antibiotic pretreatment trended toward greater remission after six weeks of treatment (55% vs. 18%, p=0.18), and no significant differences were found between maintenance dosing via capsules versus enema. In exploratory analyses, microbiome turnover at both the species and strain levels was extensive and significantly more pronounced in the pretreated patients. Associations were also revealed between taxonomic turnover and changes in the composition of primary and secondary bile acids. Together these findings suggest that antibiotic pretreatment contributes to microbiome engraftment and possibly clinical effectiveness, and validate longitudinal strain tracking as a powerful way to monitor the dynamics and impact of microbiota transfer.Competing Interest Statement- YMP is an employee of Symbiome, Inc. - ZK is an employee/shareholder at Finch Therapeutics - SVL is co-founder and shareholder of Siolta Therapeutics, Inc. and serves as both a consultant and a member of its Board of Directors. - KSP is on the scientific advisory board of Phylagen. - NE has received research support from Finch Therapeutics and Assembly Biosciences, and has been a consultant for Federation Bio and Ferring Pharmaceuticals. - All other authors declare no competing interestsClinical TrialNCT03006809 (ClinicalTrials.gov)Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT03006809 Funding Statement- BJS and BZ are supported by funding from the National Institutes of Health grant number 5T32DK007007. - KSP and BJS were supported by funding from National Science Foundation grant number 1563159, Chan Zuckerberg Biohub, and Gladstone Institutes. - NE, MZ and YMP were supported by funding from the Kenneth Rainin FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent for voluntary participation in this institutional review board-approved protocol (UCSF IRB study number: 16-20066). FMT was approved for use for this indication under FDA Investigational New Drug application (IND 16467). This study was registered at Clinicaltrials.gov (NCT03006809).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAmplicon sequences from the 16S rRNA gene and metagenomic sequences with human reads removed were uploaded to the SRA under BioProject PRJNA737472 and will be released upon publication. All code and metadata needed to reproduce our results will be available at <;https://github.com/bsmith89/ucfmt2> upon publication. https://github.com/bsmith89/ucfmt2 https://www.ncbi.nlm.nih.gov/bioproject/PRJNA737472